secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIPELLA PHARMACEUTICALS INC. (LIPO)
CIK:        0001347242
Form:       8-K
Filed at:   2025-09-18T23:59:59+00:00
Accession:  0001753926-25-001525
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipella reports positive Phase 2a results for LP-10 in oral lichen planus; all efficacy endpoints met
--------------------------------------------------------------------------------

- All 27 patients completed 4-week treatment; no serious adverse events reported.
- 76% of tacrolimus blood measurements undetectable (<1.0 ng/mL); dry mouth in 18.5%.
- Statistically significant improvements (p<0.05) in IGA, REU, pain, sensitivity, and OLPSSM at week 4.
- Company advancing LP-10 into Phase 2b; preparing protocol with FDA feedback.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347242/000175392625001525/0001753926-25-001525-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347242/000175392625001525/g084955_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-25-001525

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer